Your browser doesn't support javascript.
Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives.
Vivekanandhan, Karthik; Shanmugam, Poornima; Barabadi, Hamed; Arumugam, Vigneshwaran; Daniel Raj Daniel Paul Raj, Dharun; Sivasubramanian, Manikandan; Ramasamy, Subbaiya; Anand, Krishnan; Boomi, Pandi; Chandrasekaran, Balakumar; Arokiyaraj, Selvaraj; Saravanan, Muthupandian.
  • Vivekanandhan K; Department of Biotechnology, K. S. Rangasamy College of Technology, Tiruchengode, Tamilnadu, India.
  • Shanmugam P; Department of Biotechnology, K. S. Rangasamy College of Technology, Tiruchengode, Tamilnadu, India.
  • Barabadi H; Department of Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Arumugam V; School of Biosciences and Technology, Vellore Institute of Technology, Vellore, India.
  • Daniel Raj Daniel Paul Raj D; Department of Biotechnology, Maulana Abul Kalam Azad University of Technology, Haringhata, India.
  • Sivasubramanian M; Department of Biotechnology, Saveetha School of Engineering, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India.
  • Ramasamy S; Department of Biological Sciences, School of Mathematics and Natural Sciences, The Copperbelt University, Riverside, Zambia.
  • Anand K; Department of Chemical Pathology, School of Pathology, Faculty of Health Sciences and National Health Laboratory Service, University of the Free State, Bloemfontein, South Africa.
  • Boomi P; Department of Bioinformatics, Alagappa University, Karaikudi, India.
  • Chandrasekaran B; Faculty of Pharmacy, Philadelphia University, Amman, Jordan.
  • Arokiyaraj S; Department of Food Science and Biotechnology, Sejong University, Seoul, South Korea.
  • Saravanan M; Department of Microbiology and Immunology, Division of Biomedical Science, School of Medicine, College of Health Science, Mekelle University, Mekelle, Ethiopia.
Front Mol Biosci ; 8: 604447, 2021.
Article in English | MEDLINE | ID: covidwho-1150699
ABSTRACT
Coronavirus disease (COVID-19) has emerged as a fast-paced epidemic in late 2019 which is disrupting life-saving immunization services. SARS-CoV-2 is a highly transmissible virus and an infectious disease that has caused fear among people across the world. The worldwide emergence and rapid expansion of SARS-CoV-2 emphasizes the need for exploring innovative therapeutic approaches to combat SARS-CoV-2. The efficacy of some antiviral drugs such as remdesivir, favipiravir, umifenovir, etc., are still tested against SARS-CoV-2. Additionally, there is a large global effort to develop vaccines for the protection against COVID-19. Because vaccines seem the best solution to control the pandemic but time is required for its development, pre-clinical/clinical trials, approval from FDA and scale-up. The nano-based approach is another promising approach to combat COVID-19 owing to unique physicochemical properties of nanomaterials. Peptide based vaccines emerged as promising vaccine candidates for SARS-CoV-2. The study emphasizes the current therapeutic approaches against SARS-CoV-2 and some of the potential candidates for SARS-CoV-2 treatment which are still under clinical studies for their effectiveness against SARS-CoV-2. Overall, it is of high importance to mention that clinical trials are necessary for confirming promising drug candidates and effective vaccines and the safety profile of the new components must be evaluated before translation of in vitro studies for implementation in clinical use.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Journal: Front Mol Biosci Year: 2021 Document Type: Article Affiliation country: Fmolb.2021.604447

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Journal: Front Mol Biosci Year: 2021 Document Type: Article Affiliation country: Fmolb.2021.604447